DrugPatentWatch Database Preview
Foldrx Pharms Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for FOLDRX PHARMS, and when can generic versions of FOLDRX PHARMS drugs launch?
FOLDRX PHARMS has two approved drugs.
There are five US patents protecting FOLDRX PHARMS drugs.
There are forty-seven patent family members on FOLDRX PHARMS drugs in twenty-three countries and thirteen supplementary protection certificates in twelve countries.
Summary for Foldrx Pharms
| International Patents: | 47 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Foldrx Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 7,214,696 | Start Trial | Start Trial | ||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 8,168,663 | Start Trial | Y | Y | Start Trial | ||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | 9,770,441 | Start Trial | Y | Y | Start Trial | ||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 8,653,119 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Foldrx Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2017107235 | Start Trial |
| Taiwan | I644902 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004056315 | Start Trial |
| Canada | 2903194 | Start Trial |
| China | 106715405 | Start Trial |
| South Korea | 102004059 | Start Trial |
| Japan | 2006511612 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Foldrx Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1587821 | 2012/007 | Ireland | Start Trial | PRODUCT NAME: VYNDAQEL- TAFAMIDIS MEGLUMINE; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | CR 2012 00006 | Denmark | Start Trial | PRODUCT NAME: TAFAMIDIS (SOM MEGLUMIN); REG. NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 12C0008 | France | Start Trial | PRODUCT NAME: TAFAMIDIS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 91935 | Luxembourg | Start Trial | 91935, EXPIRES: 20261116 |
| 1587821 | CA 2012 00006 | Denmark | Start Trial | |
| 1587821 | SPC/GB12/009 | United Kingdom | Start Trial | PRODUCT NAME: TAFAMIDIS, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE MEGLUMINE SALT; REGISTERED: UK EU/1/11/717/001 20111118 |
| 1587821 | 382 | Finland | Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
